Compare EQT & RVMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EQT | RVMD |
|---|---|---|
| Founded | 1925 | 2014 |
| Country | United States | United States |
| Employees | 1873 | 883 |
| Industry | Oil & Gas Production | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.6B | 30.1B |
| IPO Year | 1994 | N/A |
| Metric | EQT | RVMD |
|---|---|---|
| Price | $50.75 | $161.65 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 21 | 19 |
| Target Price | $69.15 | ★ $140.84 |
| AVG Volume (30 Days) | ★ 5.1M | 2.5M |
| Earning Date | 04-21-2026 | 05-06-2026 |
| Dividend Yield | ★ 1.12% | N/A |
| EPS Growth | ★ 635.56 | N/A |
| EPS | ★ 2.36 | N/A |
| Revenue | ★ $8,644,211,000.00 | N/A |
| Revenue This Year | $20.28 | N/A |
| Revenue Next Year | N/A | $533.02 |
| P/E Ratio | $21.48 | ★ N/A |
| Revenue Growth | ★ 63.92 | N/A |
| 52 Week Low | $48.47 | $34.00 |
| 52 Week High | $68.24 | $166.50 |
| Indicator | EQT | RVMD |
|---|---|---|
| Relative Strength Index (RSI) | 31.94 | 61.78 |
| Support Level | $48.86 | $141.22 |
| Resistance Level | $57.62 | $166.50 |
| Average True Range (ATR) | 1.24 | 6.70 |
| MACD | -0.20 | 0.20 |
| Stochastic Oscillator | 8.97 | 85.99 |
EQT is an independent natural gas production company. It focuses its operations in the cores of the Marcellus and Utica shales, located in the Appalachian Basin in the Eastern United States. Its main customers include marketers, utilities, and industrial operators in the Appalachian Basin. The company has three reportable segments in production, gathering, and its transmission segment, which is now an operated joint venture with Blackstone. All the firm's operating revenue is generated in the US, with most revenue flowing from the Marcellus Shale field and through the sale of natural gas.
Revolution Medicines Inc is a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers. The Company possesses structure-based drug discovery capabilities built upon chemical biology and cancer pharmacology know-how and proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites. Its research and development pipeline comprises inhibitors that bind directly to RAS variants (RAS(ON) Inhibitors), designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or other therapeutic agents.